SOM Biotech closes an internal round for €5.5 Million

posted on March 13, 2024

Barcelona, Spain. March 12, 2024. SOM Biotech (“SOM” or the “Company”), a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent (AI) platform, announces the closure of an internal round for € 5.5 million to secure the completion of the Phase IIb study on Huntington patients with its lead candidate SOM3355.

Press Release